Novel agents for relapsed or refractory IP-LBCL
| . | Study design (no. of patients) . | Response rate . | Long-term efficacy . | Reference . |
|---|---|---|---|---|
| BTK inhibitors | ||||
| Ibrutinib | Phase 1 (N = 13) | ORR = 77%, CR = 38% | Median PFS = 4.6 mo | 102 |
| Phase 2 (N = 52) | ORR = 52%, CR = 19% | Median PFS = 4.8 mo | 103 | |
| Tirabrutinib | Phase 2 (N = 44) | ORR = 64%, CR = 34% | Median PFS = 2.9 mo | 105 |
| Immunomodulatory agents | ||||
| Lenalidomide | Phase 1 (N = 7) | ORR = 86%, CR = 14% | Not reported | 110 |
| Lenalidomide with rituximab | Phase 2 (N = 45) | ORR = 36%, CR = 29% | Median PFS = 7.8 mo | 111 |
| Pomalidomide with dexamethasone | Phase 1 (N = 25) | ORR = 48%, CR = 32% | Median PFS = 5.3 mo | 112 |
| Immune checkpoint inhibitors | ||||
| Nivolumab | Phase 2 PCNSL (N = 47) | ORR = 6% | Median PFS = 1.4 mo | Clinicaltrials.gov [NCT02857426] |
| Phase 2 PTL (N = 19) | ORR = 26% | Median PFS = 1.7 mo | Clinicaltrials.gov [NCT02857426] | |
| Pembrolizumab | Phase 2 PCNSL (N = 50) | ORR = 12% | Median PFS = 2.6 mo | 75 |
| CAR T-cell therapy | ||||
| Tisangenlecleucel | Phase 1/2 (N = 12) | ORR = 58%, CR = 50% | Not reported | 113 |
| Axicabtagene ciloleucel | Phase 1 (N = 9) | ORR = 86%, CR = 86% | Not reported | 114 |
| . | Study design (no. of patients) . | Response rate . | Long-term efficacy . | Reference . |
|---|---|---|---|---|
| BTK inhibitors | ||||
| Ibrutinib | Phase 1 (N = 13) | ORR = 77%, CR = 38% | Median PFS = 4.6 mo | 102 |
| Phase 2 (N = 52) | ORR = 52%, CR = 19% | Median PFS = 4.8 mo | 103 | |
| Tirabrutinib | Phase 2 (N = 44) | ORR = 64%, CR = 34% | Median PFS = 2.9 mo | 105 |
| Immunomodulatory agents | ||||
| Lenalidomide | Phase 1 (N = 7) | ORR = 86%, CR = 14% | Not reported | 110 |
| Lenalidomide with rituximab | Phase 2 (N = 45) | ORR = 36%, CR = 29% | Median PFS = 7.8 mo | 111 |
| Pomalidomide with dexamethasone | Phase 1 (N = 25) | ORR = 48%, CR = 32% | Median PFS = 5.3 mo | 112 |
| Immune checkpoint inhibitors | ||||
| Nivolumab | Phase 2 PCNSL (N = 47) | ORR = 6% | Median PFS = 1.4 mo | Clinicaltrials.gov [NCT02857426] |
| Phase 2 PTL (N = 19) | ORR = 26% | Median PFS = 1.7 mo | Clinicaltrials.gov [NCT02857426] | |
| Pembrolizumab | Phase 2 PCNSL (N = 50) | ORR = 12% | Median PFS = 2.6 mo | 75 |
| CAR T-cell therapy | ||||
| Tisangenlecleucel | Phase 1/2 (N = 12) | ORR = 58%, CR = 50% | Not reported | 113 |
| Axicabtagene ciloleucel | Phase 1 (N = 9) | ORR = 86%, CR = 86% | Not reported | 114 |
CR, complete response rate; ORR, overall response rate.